Nuvectis Pharma Commences Underwritten Public Offering

Nuvectis Pharma, a clinical-stage biopharmaceutical company, announced the commencement of an underwritten public offering of its common stock. All shares in the offering will be sold by Nuvectis, with underwriters granted a 30-day option to purchase up to an additional 15% of shares. Cantor is acting as the sole book runner for the offering. The company intends to use the net proceeds to advance its NXP100, NXP200, and NXP900 development programs, as well as for hiring, capital expenditures, and general corporate purposes.